Related Experiment Video
Updated: Jul 3, 2026

Dissecting Host-virus Interaction in Lytic Replication of a Model Herpesvirus
Published on: October 7, 2011
Alphavirus M1 disrupts super-enhancer-driven oncogenic transcription via non-structural protein NSP2 in osteosarcoma
Jiajun Zhang1,2, Lifeng Yin1,2, Qianqian Han3
1Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Abstract:
Oncolytic virotherapy has shown promise for various cancers, but its application in osteosarcoma (OS) remains underexplored. This study provides evidence that M1, a natural Getah-like alphavirus, exerts oncolytic activity against OS. We demonstrate that OS cells exhibit heightened sensitivity to M1 infection, with its anti-tumor effects not solely dependent on the canonical ER stress-induced apoptosis. Proteomic and ChIP-seq analyses show the DNA-directed RNA polymerase II subunit RPB1 contributes to oncogenic super-enhancer activity and serves as a direct target of M1-mediated regulation. The oncolytic potency correlated positively with the transcriptional dependency on RPB1 within super-enhancer regions. Mechanistically, the viral non-structural protein NSP2 disrupts super-enhancer activity by recruiting the CUL2-RBX1-ELOC complex, which triggers K63-linked ubiquitination and degradation of RPB1. Together, these findings uncover a previously unrecognized mechanism underlying M1 activity in osteosarcoma, support further preclinical evaluation of M1 in this setting, and identify RPB1 as a candidate biomarker for virotherapy response.
Insights
This study shows that the M1 alphavirus effectively targets osteosarcoma (OS) cells, offering a new avenue for cancer therapy. The virus works by degrading a key protein, RPB1, essential for cancer cell growth.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Oncolytic virotherapy shows potential against various cancers.
- Osteosarcoma (OS) remains an underexplored area for virotherapy applications.
Purpose of the Study:
- To investigate the oncolytic activity of the M1 alphavirus against osteosarcoma.
- To elucidate the underlying molecular mechanisms of M1's anti-tumor effects in OS.
Main Methods:
- Cell culture and infection with M1 alphavirus.
- Proteomic analysis and Chromatin Immunoprecipitation sequencing (ChIP-seq).
- Investigation of viral protein interactions and ubiquitination pathways.
Main Results:
- M1 virus exhibits significant oncolytic activity against OS cells.
- M1 infection targets the DNA-directed RNA polymerase II subunit RPB1, crucial for super-enhancer activity.
- Viral protein NSP2 disrupts super-enhancer activity by degrading RPB1 via a specific protein complex.
Conclusions:
- M1 alphavirus demonstrates potent oncolytic activity in osteosarcoma.
- A novel mechanism involving RPB1 degradation by M1 is identified.
- RPB1 is proposed as a potential biomarker for predicting response to M1 virotherapy in OS.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Abnormal Proliferation
Leaky Scanning
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
